Stockreport

PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines [Seeking Alpha]

PepGen Inc.  (PEPG) 
PDF PGN-EDODM1 leverages proprietary EDO technology to target myotonic dystrophy type 1 (DM1) by restoring normal splicing function of MBNL1. Phase 1 data showed dose-dep [Read more]